Unknown

Dataset Information

0

Semi-Synthesis of Marine-Derived Ilamycin F Derivatives and Their Antitubercular Activities.


ABSTRACT: Tuberculosis (TB) is still a global disease threatening people's lives. With the emergence of multi-drug-resistant Mycobacterium tuberculosis the prevention and control of tuberculosis faces new challenges, and the burden of tuberculosis treatment is increasing among the world. Ilamycins are novel cyclopeptides with potent anti-TB activities, which have a unique target protein against M. tuberculosis and drug-resistant strains. Herein, ilamycin F, a major secondary metabolite isolated from the marine-derived mutant strain Streptomyces atratus SCSIO ZH16 ΔilaR, is used as a scaffold to semi-synthesize eighteen new ilamycin derivatives (ilamycin NJL1-NJL18, 1-18). Our study reveals that four of ilamycin NJLs (1, 6, 8, and 10) have slightly stronger anti-TB activities against Mtb H37Rv (minimum inhibitory concentration, 1.6-1.7 μM) compared with that of ilamycin F on day 14th, but obviously display more potent activities than ilamycin F on day 3rd, indicating anti-TB activities of these derivatives with fast-onset effect. In addition, cytotoxic assays show most ilamycin NJLs with low cytotoxicity except ilamycin NJL1 (1). These findings will promote the further exploration of structure-activity relationships for ilamycins and the development of anti-TB drugs.

SUBMITTER: Li J 

PROVIDER: S-EPMC8586704 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Semi-Synthesis of Marine-Derived Ilamycin F Derivatives and Their Antitubercular Activities.

Li Jun J   Liu Zhiyong Z   Hong Mingye M   Sun Changli C   Zhang Tianyu T   Zhang Hua H   Ju Jianhua J   Ma Junying J  

Frontiers in chemistry 20211029


Tuberculosis (TB) is still a global disease threatening people's lives. With the emergence of multi-drug-resistant <i>Mycobacterium tuberculosis</i> the prevention and control of tuberculosis faces new challenges, and the burden of tuberculosis treatment is increasing among the world. Ilamycins are novel cyclopeptides with potent anti-TB activities, which have a unique target protein against <i>M. tuberculosis</i> and drug-resistant strains. Herein, ilamycin F, a major secondary metabolite isola  ...[more]

Similar Datasets

| S-EPMC10620885 | biostudies-literature
| S-EPMC6332143 | biostudies-literature
| S-EPMC8457714 | biostudies-literature
| S-EPMC7397056 | biostudies-literature
| S-EPMC4849068 | biostudies-literature
| S-EPMC10155492 | biostudies-literature
| S-EPMC7087588 | biostudies-literature
| S-EPMC6117713 | biostudies-literature
| S-EPMC6669556 | biostudies-literature
| S-EPMC4958353 | biostudies-literature